2nd Quarter - Report

BOCKORNY GROUP, INC. for GENERIC PHARMACEUTICAL ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 21, 2014 $50,000 Replaced
2nd Quarter - Amendment Jan 21, 2016 $50,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues relating to Patent Settlements. S. 214, Preserve Access to Affordable Generics Act

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
TODD THORPE —
NICOLE VENABLE —

Contacted: Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); White House Office

Bills named: S. 214 (113th)

Budget/Appropriations BUD

Ag-appropriations language related to labeling issues

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
TODD THORPE —
NICOLE VENABLE —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; Food & Drug Administration (FDA); SENATE

Health Issues HCR

H.R. 3204, Drug Quality and Security Act H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013 S. 1413, FDA User Fee Protection Act S. 504, Fair And Immediate Release of Generic Drugs Act

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
TODD THORPE —
NICOLE VENABLE —

Contacted: Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 504 (113th), S. 1413 (113th), H.R. 3204 (113th), H.R. 2725 (113th)

Pharmacy PHA

S.959, Pharmaceutical Quality, Security, and Accountability Act Issues Related to Biosimilar Regulation, Labeling, E-Labeling and Access Issues Related to the newly-formed Affordable Medicine Caucus

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
TODD THORPE —
NICOLE VENABLE —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: S. 959 (113th)

Trade (domestic/foreign) TRD

Issues Related to Ongoing Trans-Pacific Partnership (TPP) Negotiations (No Specific Legislation) Issues Related to the Renewal of Trade Promotion Authority (TPA)

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
TODD THORPE —
NICOLE VENABLE —

Contacted: Food & Drug Administration (FDA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Issues Relating to Medicare Part D

LobbyistCovered position, as disclosed
DAVID BOCKORNY —
MARTINA L. BRADFORD —
BLAIR C LARKINS —
TODD THORPE —
NICOLE VENABLE —

Contacted: U.S. Trade Representative (USTR); White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.